Figure F-92 is titled “Change in CAPS for atypical antipsychotics compared with placebo.” The figure displays a forest plot reporting the weighted mean difference in CAPS scores for atypical antipsychotics versus placebo stratified by risperidone versus placebo and olanzapine versus placebo. The plot depicts greater reductions in CAPS scores for patients treated with risperidone (4 trials, weighted mean difference −4.60, 95% CI −9.01 to −0.20, I2=22.3%) or olanzapine (1 trial, weighted mean difference −12.13, 95% CI −23.29 to −0.97) than placebo. The overall analysis favored atypical antipsychotics (weighted mean difference −5.76, 95% CI −10.35 to −1.17, I2=30.7%).

Figure F-92Change in CAPS for atypical antipsychotics compared with placebo

Timing of outcome assessment: 5 weeks (Hamner, 2003), 16 weeks (Bartzokis, 2003), 8 weeks (Reich, 2004), 24 weeks (Krystal, 2011), 8 weeks (Stein, 2002).

From: Appendix F, Meta-Analysis

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.